The industry’s use of comparator trials is growing. Drug companies must focus on quality if they are to reap the benefits – and reduce the risks – of comparator clinical studies. The pharmaceutical industry’s expectation for comparative effectiveness research continues to increase as international governments battle to contain rising healthcare costs – with payers, physicians and patients increasingly seeking evidence of how treatments compare in safety, efficacy and also value. Dr Bashir Parkar of BAP Pharma evaluates the changing model for pharmaceutical R&D and the regulatory environment that governs it.
Logistics 2 – Comparative